Small Molecules and Peptides Targeting Glial Cell Line-Derived Neurotrophic Factor Receptors for the Treatment of Neurodegeneration
| Autor: | Sidorova, Yulia A., Saarma, Mart |
|---|---|
| Přispěvatelé: | Divisions of Faculty of Pharmacy, Institute of Biotechnology, Helsinki Institute of Life Science HiLIFE, Joint Activities |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs)
neuropathic pain GDNF FAMILY ALPHA-SYNUCLEIN Parkinson's disease small molecule neurodegeneration WEIGHT-LOSS GFL mimetic NEURONS-IN-VITRO GENE DELIVERY RET agonist DOUBLE-BLIND retinitis pigmentosa RAT MODEL SURVIVAL 1182 Biochemistry cell and molecular biology NEURTURIN PARKINSON DISEASE receptor tyrosine kinase Rearranged in Transfection (RET) |
| Popis: | Glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) are able to promote the survival of multiple neuronal populations in the body and, therefore, hold considerable promise for disease-modifying treatments of diseases and conditions caused by neurodegeneration. Available data reveal the potential of GFLs for the therapy of Parkinson's disease, neuropathic pain and diseases caused by retinal degeneration but, also, amyotrophic lateral sclerosis and, possibly, Alzheimer's disease. Despite promising data collected in preclinical models, clinical translation of GFLs is yet to be conducted. The main reasons for the limited success of GFLs clinical development are the poor pharmacological characteristics of GFL proteins, such as the inability of GFLs to cross tissue barriers, poor diffusion in tissues, biphasic dose-response and activation of several receptors in the organism in different cell types, along with ethical limitations on patients' selection in clinical trials. The development of small molecules selectively targeting particular GFL receptors with improved pharmacokinetic properties can overcome many of the difficulties and limitations associated with the clinical use of GFL proteins. The current review lists several strategies to target the GFL receptor complex with drug-like molecules, discusses their advantages, provides an overview of available chemical scaffolds and peptides able to activate GFL receptors and describes the effects of these molecules in cultured cells and animal models. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|